Business
Director/PDMR Shareholding
Director/PDMR Shareholding.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 7870V N4 Pharma PLC 10 April 2019 \n\n10 April 2019\n \nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\n \nDirector/PDMR shareholding\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, announces that Nigel Theobald, Chief Executive Officer of the Company, has purchased 67,343 ordinary shares in the Company (\"Ordinary Shares\") at a price of 4.44 pence per Ordinary Share. In addition, Anne-Marie Lawrence, wife of Nigel Theobald and a person closely associated with him, has today purchased 67,343 Ordinary Shares at a price of 4.44 pence per Ordinary Share.\n \nAs a result of these purchases, Nigel Theobald's interest in the Company is now 16,981,319 Ordinary Shares, which represents approximately 16.74 per cent. of Company's issued share capital. \n \nEnquiries: \n \n\n\n\nN4 Pharma Plc\nNigel Theobald, CEO\n\n\n \nVia Alma PR\n \n\n\n\n\nAllenby Capital Limited\nJames Reeve/Asha Chotai\n \n\n\nTel: +44(0)203 328 5656\n\n\n\n\nScott PR\nGeorgia Smith\n\n\nTel: +44(0)1477 539 539\n\n\n\n \nAbout N4 Pharma plc\n \nN4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.\nN4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.\n \nNotification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:\n \n\n\n\n1\n \n\n\nDetails of the person discharging managerial responsibilities / person closely associated\n \n\n\n\n\na)\n \n\n\nName\n\n\nNigel Theobald\n\n\n\n\n2\n \n\n\nReason for the notification\n \n\n\n\n\na)\n \n\n\nPosition/status\n \n\n\nChief Executive Officer\n\n\n\n\nb)\n \n\n\nInitial notification /Amendment\...